{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Esophagus&page=4", "query": { "condition": "Metastatic Adenocarcinoma of the Esophagus", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 107, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Esophagus&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Adenocarcinoma+of+the+Esophagus&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T15:46:54.637Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00005876", "title": "Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "rubitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005876" }, { "nct_id": "NCT06203600", "title": "Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Esophageal Adenocarcinoma", "Advanced Gastric Adenocarcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2024-06-24", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 376, "location_summary": "Little Rock, Arkansas • Anaheim, California • Baldwin Park, California + 286 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06203600" }, { "nct_id": "NCT02872116", "title": "Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2031, "start_date": "2016-10-12", "completion_date": "2024-06-06", "has_results": true, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 27, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02872116" }, { "nct_id": "NCT07182149", "title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HNSCC", "ESCC", "Esophageal Adenocarcinoma", "Gastric Adenocarcinoma", "GEJ Adenocarcinoma", "Ovarian Cancer", "NSCLC", "Cervical Cancer", "Endometrial Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "NRM-823", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Normunity AccelCo, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-10-30", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 18, "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07182149" }, { "nct_id": "NCT00054457", "title": "Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2003-09", "completion_date": "2008-02", "has_results": false, "last_update_posted_date": "2016-12-13", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 28, "location_summary": "Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 20 more", "locations": [ { "city": "Chanute", "state": "Kansas" }, { "city": "Dodge City", "state": "Kansas" }, { "city": "El Dorado", "state": "Kansas" }, { "city": "Kingman", "state": "Kansas" }, { "city": "Liberal", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054457" }, { "nct_id": "NCT02358863", "title": "Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "Docetaxel/Capecitabine", "type": "DRUG" }, { "name": "Cisplatin/Irinotecan", "type": "DRUG" }, { "name": "Cisplatin/Docetaxel", "type": "DRUG" }, { "name": "IRI/EPI", "type": "DRUG" }, { "name": "EPI/Docetaxel", "type": "DRUG" }, { "name": "Irinotecan/Docetaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2015-02", "completion_date": "2016-11", "has_results": true, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358863" }, { "nct_id": "NCT00066716", "title": "Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "celecoxib", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2003-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-12-08", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066716" }, { "nct_id": "NCT00020761", "title": "Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2000-04", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 4, "location_summary": "Los Angeles, California • Chicago, Illinois • Portland, Oregon", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020761" }, { "nct_id": "NCT01142388", "title": "Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Esophageal Adenocarcinoma", "Metastatic Esophageal Squamous Cell Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Recurrent Esophageal Adenocarcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Esophageal Squamous Cell Carcinoma", "Recurrent Gastroesophageal Junction Adenocarcinoma", "Stage IV Esophageal Cancer AJCC v7" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2010-09-21", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 232, "location_summary": "Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 173 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142388" }, { "nct_id": "NCT00096083", "title": "Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "isolated perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Delcath Systems Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 56, "start_date": "2004-09", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2013-10-23", "last_synced_at": "2026-10-21T15:46:54.637Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096083" } ] }